NASDAQ:IONS Ionis Pharmaceuticals - IONS Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Ionis Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $39.38 -0.37 (-0.93%) (As of 01/26/2023 12:00 AM ET) Add Compare Share Share Today's Range$38.87▼$40.0050-Day Range$37.12▼$43.0952-Week Range$28.25▼$48.82Volume677,586 shsAverage Volume1.25 million shsMarket Capitalization$5.59 billionP/E RatioN/ADividend YieldN/APrice Target$44.00 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Ionis Pharmaceuticals MarketRank™ ForecastAnalyst RatingHold2.14 Rating ScoreUpside/Downside11.7% Upside$44.00 Price TargetShort InterestN/ADividend StrengthN/ASustainability-3.58Upright™ Environmental ScoreNews Sentiment0.42Based on 21 Articles This WeekInsider TradingSelling Shares$1.62 M Sold Last QuarterProj. Earnings GrowthGrowingFrom ($2.49) to ($1.77) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.77 out of 5 starsMedical Sector846th out of 1,048 stocksPharmaceutical Preparations Industry420th out of 513 stocks 2.1 Analyst's Opinion Consensus RatingIonis Pharmaceuticals has received a consensus rating of Hold. The company's average rating score is 2.14, and is based on 3 buy ratings, 2 hold ratings, and 2 sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $44.00, Ionis Pharmaceuticals has a forecasted upside of 11.7% from its current price of $39.38.Amount of Analyst CoverageIonis Pharmaceuticals has only been the subject of 4 research reports in the past 90 days. Previous Next N/A Short Interest Short InterestThere is no current short interest data available for IONS. Previous Next 0.0 Dividend Strength Dividend YieldIonis Pharmaceuticals does not currently pay a dividend.Dividend GrowthIonis Pharmaceuticals does not have a long track record of dividend growth. Previous Next 3.0 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreIonis Pharmaceuticals has received a 27.23% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is false driven by its "Neuromuscular disorders medication" product. See details.Environmental SustainabilityThe Environmental Impact score for Ionis Pharmaceuticals is -3.58. Previous Next 3.0 News and Social Media Coverage News SentimentIonis Pharmaceuticals has a news sentiment score of 0.42. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.76 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 21 news articles for Ionis Pharmaceuticals this week, compared to 3 articles on an average week.Search Interest20 people have searched for IONS on MarketBeat in the last 30 days. This is an increase of 400% compared to the previous 30 days.MarketBeat Follows4 people have added Ionis Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 33% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Ionis Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,622,348.00 in company stock.Percentage Held by InsidersOnly 2.36% of the stock of Ionis Pharmaceuticals is held by insiders.Percentage Held by Institutions87.32% of the stock of Ionis Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Ionis Pharmaceuticals are expected to grow in the coming year, from ($2.49) to ($1.77) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Ionis Pharmaceuticals is -328.14, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Ionis Pharmaceuticals is -328.14, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioIonis Pharmaceuticals has a P/B Ratio of 7.20. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Ionis Pharmaceuticals (NASDAQ:IONS) StockIonis Pharmaceuticals, Inc. engages in the development and commercialization of human therapeutic drugs using antisense technology. It operates through the Ionis Core and Akcea Therapeutics segments. The Ionis Core segment exploits a novel drug discovery platform to generate a pipeline of drugs. The Akcea Therapeutics segment develops and commercializes drugs for cardiometabolic diseases. The company was founded by Stanley T. Crooke, David J. Ecker, Christopher K. Mirabelli, and Brett P. Monia in 1989 and is headquartered in Carlsbad, CA.Read More Receive IONS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Ionis Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address IONS Stock News HeadlinesJanuary 26, 2023 | finance.yahoo.comIonis Chief Scientific Officer C. Frank Bennett, Ph.D. to receive Rainwater Prize for Outstanding Innovation in Neurodegenerative Disease ResearchJanuary 26, 2023 | americanbankingnews.comIonis Pharmaceuticals, Inc. (NASDAQ:IONS) Forecasted to Earn Q1 2023 Earnings of ($0.45) Per ShareJanuary 26, 2023 | Investing Trends (Ad)Profit From the Commercial Solar Boom?Solar energy had its best year ever in 2021, with a record 24 gigawatts of power installed. That's enough to power 18 million homes! Analysts expect the global solar farm market to reach $356 billion by 2028. The utility segment of the solar market is expected to grow at the highest annual growth rate in the industry, especially with the many tax incentives now offered. January 25, 2023 | benzinga.comIonis Pharmaceuticals Stock (NASDAQ:IONS), Quotes and News SummaryJanuary 25, 2023 | americanbankingnews.comIonis Pharmaceuticals, Inc. Expected to Post Q4 2022 Earnings of ($0.95) Per Share (NASDAQ:IONS)January 25, 2023 | americanbankingnews.comSVB Leerink Increases Ionis Pharmaceuticals (NASDAQ:IONS) Price Target to $33.00January 23, 2023 | markets.businessinsider.comSVB Securities Reaffirms Their Hold Rating on Ionis Pharmaceuticals (IONS)January 22, 2023 | americanbankingnews.comIonis Pharmaceuticals, Inc. (NASDAQ:IONS) CEO Sells $989,856.34 in StockJanuary 26, 2023 | PressReach (Ad)Stocks News AnnouncementDon't miss this update. Read the press release about Small Pharma.January 22, 2023 | americanbankingnews.comPiper Sandler Raises Ionis Pharmaceuticals (NASDAQ:IONS) Price Target to $62.00January 21, 2023 | americanbankingnews.comEric Swayze Sells 5,631 Shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) StockJanuary 21, 2023 | americanbankingnews.comElizabeth L. Hougen Sells 8,280 Shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) StockJanuary 20, 2023 | americanbankingnews.comIonis Pharmaceuticals (NASDAQ:IONS) Shares Gap Down After Insider SellingJanuary 19, 2023 | americanbankingnews.comInsider Selling: Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Director Sells 2,000 Shares of StockJanuary 19, 2023 | americanbankingnews.comBrokerages Set Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Target Price at $43.00January 10, 2023 | finance.yahoo.comIonis Pharmaceuticals (NASDAQ:IONS) shareholders have endured a 41% loss from investing in the stock three years agoJanuary 9, 2023 | finance.yahoo.comRoyalty Pharma agrees to buy Ionis Pharma royalties for $1.125 blnJanuary 9, 2023 | finance.yahoo.comIonis and Royalty Pharma enter into royalty agreement for up to $1.1 billion to further advance Ionis' genetic medicines and commercial readinessJanuary 9, 2023 | finance.yahoo.comRoyalty Pharma and Ionis Enter Into Royalty Agreement for Up to $1.1 Billion to Further Advance Ionis’ Genetic Medicines and Commercial ReadinessJanuary 4, 2023 | finance.yahoo.comIonis to present at 41st Annual J.P. Morgan Healthcare conferenceJanuary 4, 2023 | finance.yahoo.comBiogen and Alcyone Therapeutics Announce License and Collaboration Agreement to Evaluate a Novel Device to Improve Patient Experience and Access to Neurological ASO TherapiesDecember 21, 2022 | msn.comThe Latest Analyst Ratings for Ionis PharmaceuticalsDecember 14, 2022 | proactiveinvestors.comRBC Capital Markets reveals its 2023 biotech favourites - big and smallDecember 9, 2022 | finance.yahoo.comWhy Is Ionis Pharmaceuticals (IONS) Down 16.4% Since Last Earnings Report?December 6, 2022 | finance.yahoo.comBiogen's (BIIB) ALS Drug Tofersen Filing Accepted in EuropeDecember 5, 2022 | markets.businessinsider.comIonis Announces EMA's Acceptance Of Marketing Authorization Application Of Tofersen For SOD1-ALSDecember 5, 2022 | finance.yahoo.comIonis announces European Medicines Agency accepts Marketing Authorization Application of tofersen to treat rare, genetic form of ALSSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive IONS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Ionis Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address IONS Company Calendar Last Earnings11/09/2022Today1/26/2023Next Earnings (Estimated)2/23/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryBiotechnology SectorMedical Current SymbolNASDAQ:IONS CUSIP46433010 CIK874015 Webwww.ionispharma.com Phone(760) 931-9200Fax760-603-2700Employees660Year FoundedN/APrice Target and Rating Average Stock Price Forecast$44.00 High Stock Price Forecast$64.00 Low Stock Price Forecast$30.00 Forecasted Upside/Downside+11.7%Consensus RatingHold Rating Score (0-4)2.14 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)($0.12) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-28,600,000.00 Net Margins0.91% Pretax Margin1.28% Return on Equity1.18% Return on Assets0.32% Debt Debt-to-Equity Ratio2.10 Current Ratio7.59 Quick Ratio7.52 Sales & Book Value Annual Sales$810 million Price / Sales6.91 Cash Flow$0.09 per share Price / Cash Flow425.63 Book Value$5.47 per share Price / Book7.20Miscellaneous Outstanding Shares142,050,000Free Float138,698,000Market Cap$5.59 billion OptionableOptionable Beta0.54 Key ExecutivesBrett P. MoniaChief Executive Officer & DirectorOnaiza Cadoret-ManierEVP, Chief Product Strategy & Operations OfficerElizabeth L. HougenChief Financial Officer & Executive VP-FinanceC. Frank BennettChief Scientific Officer & Executive VPSanjay BhanotChief Medical Officer & SVPKey CompetitorsMadrigal PharmaceuticalsNASDAQ:MDGLAlkermesNASDAQ:ALKSAmicus TherapeuticsNASDAQ:FOLDIronwood PharmaceuticalsNASDAQ:IRWDDynavax TechnologiesNASDAQ:DVAXView All CompetitorsInsiders & InstitutionsStrs OhioBought 8,483 shares on 1/26/2023Ownership: 0.018%Bard Financial Services Inc.Sold 33,970 shares on 1/25/2023Ownership: 0.038%Baillie Gifford & Co.Bought 8,946 shares on 1/24/2023Ownership: 0.235%National Bank of Canada FIBought 9,175 shares on 1/24/2023Ownership: 0.043%Xponance Inc.Bought 2,170 shares on 1/24/2023Ownership: 0.012%View All Insider TransactionsView All Institutional Transactions IONS Stock - Frequently Asked Questions Should I buy or sell Ionis Pharmaceuticals stock right now? 7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Ionis Pharmaceuticals in the last year. There are currently 2 sell ratings, 2 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" IONS shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in IONS, but not buy additional shares or sell existing shares. View IONS analyst ratings or view top-rated stocks. What is Ionis Pharmaceuticals' stock price forecast for 2023? 7 Wall Street analysts have issued 1 year price targets for Ionis Pharmaceuticals' shares. Their IONS share price forecasts range from $30.00 to $64.00. On average, they anticipate the company's share price to reach $44.00 in the next year. This suggests a possible upside of 11.7% from the stock's current price. View analysts price targets for IONS or view top-rated stocks among Wall Street analysts. How have IONS shares performed in 2023? Ionis Pharmaceuticals' stock was trading at $37.77 at the beginning of the year. Since then, IONS shares have increased by 4.3% and is now trading at $39.38. View the best growth stocks for 2023 here. When is Ionis Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, February 23rd 2023. View our IONS earnings forecast. How were Ionis Pharmaceuticals' earnings last quarter? Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) released its quarterly earnings data on Wednesday, November, 9th. The company reported ($0.33) EPS for the quarter, topping the consensus estimate of ($0.74) by $0.41. The company earned $160 million during the quarter, compared to the consensus estimate of $149.48 million. Ionis Pharmaceuticals had a net margin of 0.91% and a trailing twelve-month return on equity of 1.18%. What guidance has Ionis Pharmaceuticals issued on next quarter's earnings? Ionis Pharmaceuticals updated its FY 2022 earnings guidance on Friday, December, 9th. The company provided EPS guidance of for the period. The company issued revenue guidance of $575.00M-, compared to the consensus revenue estimate of $594.45 million. What other stocks do shareholders of Ionis Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Ionis Pharmaceuticals investors own include CA (CA), Micron Technology (MU), NVIDIA (NVDA), Gilead Sciences (GILD), Alibaba Group (BABA), Alnylam Pharmaceuticals (ALNY), Biogen (BIIB), BlackRock (BLK), Skyworks Solutions (SWKS) and Advanced Micro Devices (AMD). What is Ionis Pharmaceuticals' stock symbol? Ionis Pharmaceuticals trades on the NASDAQ under the ticker symbol "IONS." Who are Ionis Pharmaceuticals' major shareholders? Ionis Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional shareholders include ARK Investment Management LLC (1.88%), Allspring Global Investments Holdings LLC (0.34%), Assenagon Asset Management S.A. (0.31%), Baillie Gifford & Co. (0.23%), Peregrine Capital Management LLC (0.09%) and DAVENPORT & Co LLC (0.06%). Insiders that own company stock include B Lynne Parshall, Breaux Castleman, Brett P Monia, C Frank Bennett, Elizabeth L Hougen, Eric Swayze, Frederick T Muto, Joseph Klein III, Patrick R O'neil, Richard S Geary, Spencer R Berthelsen and Stanley T Crooke. View institutional ownership trends. How do I buy shares of Ionis Pharmaceuticals? Shares of IONS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Ionis Pharmaceuticals' stock price today? One share of IONS stock can currently be purchased for approximately $39.38. How much money does Ionis Pharmaceuticals make? Ionis Pharmaceuticals (NASDAQ:IONS) has a market capitalization of $5.59 billion and generates $810 million in revenue each year. The company earns $-28,600,000.00 in net income (profit) each year or ($0.12) on an earnings per share basis. How many employees does Ionis Pharmaceuticals have? The company employs 660 workers across the globe. How can I contact Ionis Pharmaceuticals? Ionis Pharmaceuticals' mailing address is 2855 GAZELLE COURT, CARLSBAD CA, 92010. The official website for the company is www.ionispharma.com. The company can be reached via phone at (760) 931-9200, via email at wwalke@ionisph.com, or via fax at 760-603-2700. This page (NASDAQ:IONS) was last updated on 1/26/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.